NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00430365: Phase 3 - IFM2005-02 - Maintenance Therapy Using Lenalidomide in Myeloma
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
Bortezomib before & after high-dose therapy in myeloma: phase III HOVON-65/GMMG-HD4 trial
NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating New Myeloma
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After ASCT -TT2
NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)
NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
NCT00405756: Phase 3 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM
NCT00200681 : Phase 3- IFM 2005-01: Velcade/Dex Vs Vincristine/Adriamycin/Dex (VAD) for MM
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
NCT00081939: UARK 2003-33, Total Therapy III